Application of berberine compound in preparation of plasma type kallikrein inhibitor medicine

The invention provides an application of berberine in preparation of a medicine of a plasma type kallikrein inhibitor, and the application is applied to the technical field of biological medicines.The berberine and rat serum with different concentrations are mixed and incubated for 15 min in a Tris-HCl buffer system at the temperature of 25 DEG C (50 mM Tris-HCl, 250 mM NaCl and 1.5 mu M BSA; the pH value is 7.5), and then adding a specific fluorescent substrate (Z-Phe-Arg 7-acylamino-4-methyl coumarin hydrochloride; the final concentration is 200 [mu] M), and a microplate reader is used for detecting the fluorescence intensity at 480 nm (the wavelength of excitation light is 360 nm). The final concentration ([mu] g/mL) of berberine is 0.1, 0.3, 1.0, 3.0, 10.0, 30.0, 100.0, 300.0, 1000.0 and 3000.0. IC50 ([mu] g/mL) of berberine for inhibiting PK enzyme activity is 56.04 +/-1.05, and Hill Slope is 1.08 +/-0.05, so that the berberine has an obvious inhibiting effect on PK. 本申请提供一种黄连素在制备血浆型激肽释放酶抑制剂的药物中的应用，应用于生物